A novel vaccine containing EphA2 epitope and LIGHT plasmid induces robust cellular immunity against glioma U251 cells

Cellular Immunology

Volumn 272, Issue 1, 2011, Pages 102-106

  Chen, Hongjie ^a,b   Yuan, Bangqing ^c   Zheng, Zhaocong ^a   Liu, Zheng ^a   Wang, Shousen ^a   Liu, Yong ^d  

^a FUZHOU GENERAL HOSPITAL   (China)

^b FUJIAN MEDICAL UNIVERSITY   (China)

^c The 476th Hospital of PLA   (China)

^d THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

EphA2; Glioma; Immunotherapy; LIGHT; Vaccine

Indexed keywords

EPHRIN RECEPTOR A2; GAMMA INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CELLULAR IMMUNITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENE TRANSFER; GLIOMA; HUMAN; HUMAN CELL; IMMUNIZATION; LIGHT PLASMID; LYMPHOCYTE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECOMBINANT PLASMID; TREATMENT OUTCOME; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; CANCER VACCINES; CENTRAL NERVOUS SYSTEM NEOPLASMS; CERCOPITHECUS AETHIOPS; COS CELLS; ENZYME-LINKED IMMUNOSPOT ASSAY; EPITOPES; GLIOMA; HLA-A2 ANTIGEN; IMMUNITY, CELLULAR; IMMUNIZATION; IMMUNOTHERAPY; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; OLIGOPEPTIDES; PLASMIDS; RECEPTOR, EPHA2; SURVIVAL RATE; T-LYMPHOCYTES, CYTOTOXIC;

MUS;

EID: 80455173679     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2011.08.011     Document Type: Article

References (35)

1. Katoh M., Katoh M. Comparative integromics on Eph family. International Journal of Oncology 2006, 28:1243-1247.
2. Lee J.W., Han H.D., Shahzad M.M., Kim S.W., Mangala L.S., Nick A.M., Lu C., Langley R.R., Schmandt R., Kim H.S., Mao S., Gooya J., Fazenbaker C., Jackson D., Tice D.A., Landen C.N., Coleman R.L., Sood A.K. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. Journal of the National Cancer Institute 2009, 101:1193-1205.
3. Wesa A.K., Herrem C.J., Mandic M., Taylor J.L., Vasquez C., Kawabe M., Tatsumi T., Leibowitz M.S., Finke J.H., Bukowski R.M., Bruckheimer E., Kinch M.S., Storkus W.J. Enhancement in specific CD8+ T cell recognition of EphA2+ tumors in vitro and in vivo after treatment with ligand agonists. Journal of Immunology 2008, 181:7721-7727.
4. Herrem C.J., Tatsumi T., Olson K.S., Shirai K., Finke J.H., Bukowski R.M., Zhou M., Richmond A.L., Derweesh I., Kinch M.S., Storkus W.J. Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. Clinical Cancer Research 2005, 11:226-231.
5. Margaryan N.V., Strizzi L., Abbott D.E., Seftor E.A., Rao M.S., Hendrix M.J., Hess A.R. EphA2 as a promoter of melanoma tumorigenicity. Cancer Biology and Therapy 2009, 8:279-288.
6. Zhang J., Wang Q., Zhao D., Cao X. Induction of potent anti-tumor immunity by direct injection of Ad-LIGHT at the site of tumor inoculation. Cytotherapy 2007, 9:386-396.
7. Nadiminty N., Chun J.Y., Hu Y., Dutt S., Lin X., Gao A.C. LIGHT, a member of the TNF superfamily, activates Stat3 mediated by NIK pathway. Biochemical and Biophysical Research Communications 2007, 359:379-384.
8. Pierer M., Brentano F., Rethage J., Wagner U., Hantzschel H., Gay R.E., Gay S., Kyburz D. The TNF superfamily member LIGHT contributes to survival and activation of synovial fibroblasts in rheumatoid arthritis. Rheumatology (Oxford, England) 2007, 46:1063-1070.
9. Cheung T.C. Modulation of T cell proliferation through the LIGHT-HVEM-BTLA cosignaling pathway. Recent Patents on DNA and Gene Sequences 2009, 3:177-182.
10. Heo S.K., Yoon M.A., Lee S.C., Ju S.A., Choi J.H., Suh P.G., Kwon B.S., Kim B.S. HVEM signaling in monocytes is mediated by intracellular calcium mobilization. Journal of Immunology 2007, 179:6305-6310.
11. R Brown G., Lee E.L., El-Hayek J., Kintner K., Luck C. IL-12-independent LIGHT signaling enhances MHC class II disparate CD4+ T cell alloproliferation, IFN-gamma responses, and intestinal graft-versus-host disease. Journal of Immunology 2005, 174:4688-4695.
12. Clavreul A., Jean I., Preisser L., Chassevent A., Sapin A., Michalak S., Menei P. Human glioma cell culture: two FCS-free media could be recommended for clinical use in immunotherapy. In Vitro Cellular and Developmental Biology 2009, 45:500-511.
13. Yamanaka R. Dendritic-cell- and peptide-based vaccination strategies for glioma. Neurosurgical Review 2009, 32:265-273. discussion 273.
14. Izumoto S., Tsuboi A., Oka Y., Suzuki T., Hashiba T., Kagawa N., Hashimoto N., Maruno M., Elisseeva O.A., Shirakata T., Kawakami M., Oji Y., Nishida S., Ohno S., Kawase I., Hatazawa J., Nakatsuka S., Aozasa K., Morita S., Sakamoto J., Sugiyama H., Yoshimine T. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. Journal of Neurosurgery 2008, 108:963-971.
15. Bigner D.D., Pitts O.M., Wikstrand C.J. Induction of lethal experimental allergic encephalomyelitis in nonhuman primates and guinea pigs with human glioblastoma multiforme tissue. Journal of Neurosurgery 1981, 55:32-42.
16. Walker D.G., Laherty R., Tomlinson F.H., Chuah T., Schmidt C. Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy. Journal of Clinical Neuroscience 2008, 15:114-121.
17. Kim C.H., Woo S.J., Park J.S., Kim H.S., Park M.Y., Park S.D., Hong Y.K., Kim T.G. Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma. Immunology 2007, 122:615-622.
18. Ishikawa E., Tsuboi K., Saijo K., Harada H., Takano S., Nose T., Ohno T. Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Research 2004, 24:1861-1871.
19. Mudali S.V., Fu B., Lakkur S.S., Luo M., Embuscado E.E., Iacobuzio-Donahue C.A. Patterns of EphA2 protein expression in primary and metastatic pancreatic carcinoma and correlation with genetic status. Clinical and Experimental Metastasis 2006, 23:357-365.
20. Herath N.I., Spanevello M.D., Sabesan S., Newton T., Cummings M., Duffy S., Lincoln D., Boyle G., Parsons P.G., Boyd A.W. Over-expression of Eph and ephrin genes in advanced ovarian cancer: ephrin gene expression correlates with shortened survival. BMC Cancer 2006, 6:144.
21. Nakamura R., Kataoka H., Sato N., Kanamori M., Ihara M., Igarashi H., Ravshanov S., Wang Y.J., Li Z.Y., Shimamura T., Kobayashi T., Konno H., Shinmura K., Tanaka M., Sugimura H. EPHA2/EFNA1 expression in human gastric cancer. Cancer Science 2005, 96:42-47.
22. Wang L., Fokas F.E., Bieker M., Rose F., Rexin P., Zhu Y., Pagenstecher A., Engenhart-Cabillic R., An H.X. Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients. Oncology Reports 2008, 19:151-156.
23. Wykosky J., Gibo D.M., Debinski W. A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells. Molecular Cancer Therapeutics 2007, 6:3208-3218.
24. Wykosky J., Gibo D.M., Stanton C., Debinski W. EphA2 as a novel molecular marker and target in glioblastoma multiforme. Molecular Cancer Research 2005, 3:541-551.
25. Tatsumi T., Herrem C.J., Olson W.C., Finke J.H., Bukowski R.M., Kinch M.S., Ranieri E., Storkus W.J. Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Research 2003, 63:4481-4489.
26. Ware C.F. Targeting the LIGHT-HVEM pathway. Advances in Experimental Medicine and Biology 2009, 647:146-155.
27. Ware C.F. Targeting lymphocyte activation through the lymphotoxin and LIGHT pathways. Immunological Reviews 2008, 223:186-201.
28. Yu P., Fu Y.X. Targeting tumors with LIGHT to generate metastasis-clearing immunity. Cytokine and Growth Factor Reviews 2008, 19:285-294.
29. Morishige T., Yoshioka Y., Inakura H., Tanabe A., Watanabe H., Yao X., Tsunoda S., Tsutsumi Y., Mukai Y., Okada N., Nakagawa S. LIGHT protein suppresses tumor growth by augmentation of immune response. Immunology Letters 2009, 127:33-38.
30. Pasero C., Truneh A., Olive D. Cosignaling molecules around LIGHT-HVEM-BTLA: from immune activation to therapeutic targeting. Current Molecular Medicine 2009, 9:911-927.
31. Ueda R., Fujita M., Zhu X., Sasaki K., Kastenhuber E.R., Kohanbash G., McDonald H.A., Harper J., Lonning S., Okada H. Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines. Clinical Cancer Research 2009, 15:6551-6559.
32. Yamaguchi S., Tatsumi T., Takehara T., Sakamori R., Uemura A., Mizushima T., Ohkawa K., Storkus W.J., Hayashi N. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines. Cancer 2007, 110:1469-1477.
33. Hatano M., Kuwashima N., Tatsumi T., Dusak J.E., Nishimura F., Reilly K.M., Storkus W.J., Okada H. Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors. Journal of Translational Medicine 2004, 2:40.
34. Kim J.H., Kang T.H., Noh K.H., Kim S.H., Lee Y.H., Kim K.W., Bae H.C., Ahn Y.H., Choi E.Y., Kim J.S., Lee K.M., Kim T.W. Enhancement of DC vaccine potency by activating the PI3K/AKT pathway with a small interfering RNA targeting PTEN. Immunology Letters 2010, 134:47-54.
35. Yang J.Y., Cao D.Y., Liu W.C., Zhang H.M., Teng Z.H., Ren J. Dendritic cell generated from CD34+ hematopoietic progenitors can be transfected with adenovirus containing gene of HBsAg and induce antigen-specific cytotoxic T cell responses. Cellular Immunology 2006, 240:14-21.